Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

592
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
592
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.2K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

614
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
614
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.4K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.4K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

3.5K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.5K
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

4.1K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunologic risk stratification of pediatric heart transplant patients by combining HLA-EMMA and PIRCHE-II.

Frontiers in immunology·2023
Same author

[Design, implementation and evaluation of an educational approach for patients with PICC line and midline].

Annales pharmaceutiques francaises·2023
Same author

Consensus statement from 2<sup>nd</sup> International Conference on Controversies in Vitamin D.

Reviews in endocrine & metabolic disorders·2020
Same author

Incidence, characterization, and impact of newly detected donor-specific anti-HLA antibody in the first year after pediatric heart transplantation: A report from the CTOTC-04 study.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2018
Same author

Patterns of kidney injury in pediatric nonkidney solid organ transplant recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Oncologist use and perception of large panel next-generation tumor sequencing.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Related Experiment Video

Updated: Apr 19, 2026

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.5K

Report from a forum on US heart allocation policy.

J A Kobashigawa, M Johnson, J Rogers

    American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
    |December 24, 2014
    PubMed
    Summary
    This summary is machine-generated.

    US heart transplant waitlists need policy updates. Experts favor a tiered system for patients with mechanical circulatory support (MCS) complications, prioritizing those with high mortality risk and addressing geographic disparities.

    More Related Videos

    Author Spotlight: Enhancing Donor Heart Preservation Through Isolated Rat Heart Perfusion Studies
    06:56

    Author Spotlight: Enhancing Donor Heart Preservation Through Isolated Rat Heart Perfusion Studies

    Published on: October 4, 2024

    1.1K
    Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
    09:20

    Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

    Published on: February 13, 2021

    7.2K

    Related Experiment Videos

    Last Updated: Apr 19, 2026

    Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
    08:49

    Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

    Published on: August 2, 2024

    1.5K
    Author Spotlight: Enhancing Donor Heart Preservation Through Isolated Rat Heart Perfusion Studies
    06:56

    Author Spotlight: Enhancing Donor Heart Preservation Through Isolated Rat Heart Perfusion Studies

    Published on: October 4, 2024

    1.1K
    Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
    09:20

    Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

    Published on: February 13, 2021

    7.2K

    Area of Science:

    • Cardiology
    • Transplant Surgery
    • Health Policy

    Background:

    • US heart allocation policy (2006) requires revision due to significant changes in transplant waitlists.
    • Advances in mechanical circulatory support (MCS) improve survival but Status 1A mortality remains high.
    • Current listing criteria may disadvantage specific patient subgroups, and geographic disparities persist.

    Purpose of the Study:

    • To discuss critical issues in US heart allocation policy.
    • To gather expert opinions on potential policy revisions.
    • To identify concepts for future policy development.

    Main Methods:

    • A forum was convened to discuss US heart allocation policy.
    • A 25-question survey on heart allocation policy was administered.
    • Participants included 84 heart transplant experts from 51 US centers and representatives from OPTN/UNOS and SRTR.

    Main Results:

    • Strong consensus for a more tiered heart allocation system.
    • Interest in prioritizing patients with MCS complications, high sensitization, severe arrhythmias, or restrictive physiology.
    • Support for geographically modified distribution based on population, though differences exist between center sizes.

    Conclusions:

    • The current US heart allocation policy needs significant revision.
    • A more refined, tiered system is favored to address patient subgroups and geographic disparities.
    • While a comprehensive heart allocation score is not yet feasible, specific patient factors warrant improved prioritization.